Search
Halozyme Therapeutics Inc
HALOAdd to Watchlist
130.340USD
+1.720+1.34%
Close 11-04 16:00（ET）
14.79BMarket Cap
44.07P/E TTM
Pre-market 07:06 (ET)132.300USD+1.960+1.50%
Pre-market 07:06 (ET)Halozyme Therapeutics Inc (HALO) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Halozyme Therapeutics Inc in the past month.
Buy
1 Strong Buy
7 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
108.834USD-16.86%
HALO Analyst Recommendation Trends
In the current month, HALO has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. HALO average Analyst price target in the last month is 108.834.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
0
0
0
0
0
0
7
7
7
6
6
6
6
6
2
2
3
3
3
2
2
2
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
10
10
10
10
10
9
9
9
HALO Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, HALO EPS is projected to reach 2.355 in FY2026Q3, following reported EPS of 1.960 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
2.20
1.53
1.84
2.35
2.62
Actual
-1.20
1.27
1.96
--
--
Surprise
-154.75%
-16.99%
+6.78%
--
--
FAQs
What is Halozyme Therapeutics Inc's expected revenue for the next quarter?
Halozyme Therapeutics Inc's expected revenue is 491.56M.
What is Halozyme Therapeutics Inc's price target?
Analysts forecast that Halozyme Therapeutics Inc's price target is USD 108.83, with the highest forecast at USD 130.00 and the lowest forecast at USD 78.00.
How have Halozyme Therapeutics IncHALO's recent earnings per share performed?
The market expectation was USD 1.96, while Halozyme Therapeutics IncHALO's earnings per share (EPS) for the previous quarter was USD 1.27. EPS for the next quarter is expected at USD 2.35.
What is the analyst rating for Halozyme Therapeutics Inc?
Based on the ratings of Halozyme Therapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.